Hanmi Pharmaceutical Targets Launch of New Obesity Drug "Efe" This Year...Commercialization Team Activated

"EFPE-PROJECT-Story" Launch Ceremony Held on the 13th

Hanmi Pharmaceutical has launched a company-wide coordination body for the commercialization of its GLP-1 (glucagon-like peptide-1) obesity treatment, "Efeglenatide" (hereafter referred to as "Efe"). The company aims to obtain marketing approval within this year and plans to integrate and manage the entire process from development to commercialization.

Juhyun Lim, Vice Chairman of Hanmi Group (fourth from the left in the front row), and Sangyeon Hwang, CEO of Hanmi Pharmaceutical (third from the left in the front row), along with executives and employees of the company's official consultative body, are taking a commemorative photo at the launch ceremony of the 'EFPE-PROJECT-Story' held on the 13th at Hanmi C&C Square. Hanmi Pharmaceutical

Hanmi Pharmaceutical announced on the 17th that it had established the "EFPE-PROJECT-Story" coordination body at Hanmi C&C Square in Songpa-gu, Seoul on the 13th. This body will oversee decision-making by integrating the functions of development, clinical trials, production, marketing, distribution, and communication strategy into a single execution system. The company intends to hold regular monthly meetings to review the progress of commercialization preparations.

The event was attended by Juhyun Lim, Vice Chairman of Hanmi Group, Sangyeon Hwang, CEO of Hanmi Pharmaceutical, and other key executives. Heads of each division, including Nayoung Kim, Head of New Product Development; Myunghee Park, Head of Domestic Marketing; and Inyoung Choi, Head of R&D Center, shared strategies for development and business operations.

Efe is a GLP-1 receptor agonist that incorporates Hanmi Pharmaceutical's long-acting platform "LAPSCOVERY." It is being developed to reduce gastrointestinal side effects and the burden of dose titration, based on its property of gradual absorption and relatively stable blood concentration. According to the company, the Phase 3 cardiovascular outcomes study confirmed a risk reduction in major cardiovascular events.

Hanmi Pharmaceutical plans to first launch Efe as an obesity treatment and then expand its indications to diabetes and other conditions. The company aims to ensure product scalability by utilizing real-world data approaches and integrating digital technologies.

From a marketing perspective, the company intends to enter the market focusing on clinical efficacy and user convenience rather than price competition. Production, distribution, and communication strategies will also be managed in an integrated manner.

Vice Chairman Lim stated, "Efe is not just another GLP-1 obesity treatment; it is a project that reflects the direction and values Hanmi has pursued throughout the entire development process. It embodies Hanmi's spirit of turning challenges into new growth engines and opportunities, rather than settling for failure."

CEO Hwang said, "We are confident that we can foster Efe as a premium, Korean-style obesity treatment, and we have also confirmed that there are still significant 'unmet needs' that existing products do not satisfy. Based on our ability to precisely identify and meet market demands, we will boldly develop Efe and Hanmi's innovative metabolic disease drugs and products as drivers of future growth."

This content was produced with the assistance of AI translation services.